theory clinical_3_6
imports Main

begin

typedecl entity
typedecl event

consts
  Loss :: "entity ⇒ bool"
  BRCA2 :: "entity ⇒ bool"
  ChromosomeBreakage :: "entity ⇒ bool"
  Causes :: "event ⇒ bool"
  Inhibition :: "entity ⇒ bool"
  PARP :: "entity ⇒ bool"
  CollapsedReplicationForks :: "entity ⇒ bool"
  DoubleStrandBreaks :: "entity ⇒ bool"
  PARPInhibitors :: "entity ⇒ bool"
  Drives :: "event ⇒ bool"
  CancerDevelopment :: "entity ⇒ bool"
  GenomicInstability :: "entity ⇒ bool"
  Trapping :: "entity ⇒ bool"
  PARP1 :: "entity ⇒ bool"
  SitesOfDoubleStrandBreaks :: "entity ⇒ bool"
  Increases :: "event ⇒ bool"
  NonHomologousEndJoining :: "entity ⇒ bool"
  Toxicity :: "entity ⇒ bool"
  Prevent :: "event ⇒ bool"
  SingleStrandBreakRepair :: "entity ⇒ bool"
  LeadsTo :: "event ⇒ bool"
  ReplicationAssociatedDoubleStrandBreaks :: "entity ⇒ bool"
  RepairedThrough :: "event ⇒ bool"
  DefectiveHomologousRecombinationRepair :: "entity ⇒ bool"
  ErrorProneNonHomologousEndJoining :: "entity ⇒ bool"
  RelianceOn :: "event ⇒ bool"
  Agent :: "event ⇒ entity ⇒ bool"
  Patient :: "event ⇒ entity ⇒ bool"

(* Explanation 1: Loss of BRCA2 causes chromosome breakage. *)
axiomatization where
  explanation_1: "∀x y. Loss x ∧ BRCA2 y ⟶ (∃e. Causes e ∧ Agent e x ∧ Patient e y ∧ ChromosomeBreakage y)"

(* Explanation 2: Inhibition of PARP results in collapsed replication forks and double strand breaks, and PARP inhibitors directly cause these double strand breaks. *)
axiomatization where
  explanation_2: "∀x y z. Inhibition x ∧ PARP y ⟶ (∃e. Causes e ∧ Agent e x ∧ Patient e z ∧ (CollapsedReplicationForks z ∧ DoubleStrandBreaks z)) ∧ (PARPInhibitors y ⟶ (∃e. Causes e ∧ Agent e y ∧ Patient e z ∧ DoubleStrandBreaks z))"

(* Explanation 3: Loss of BRCA2 drives cancer development via genomic instability. *)
axiomatization where
  explanation_3: "∀x y z. Loss x ∧ BRCA2 y ⟶ (∃e. Drives e ∧ Agent e x ∧ Patient e z ∧ CancerDevelopment z ∧ GenomicInstability z)"

(* Explanation 4: Trapping of PARP1 at sites of double strand breaks increases non-homologous end joining and increases toxicity. *)
axiomatization where
  explanation_4: "∀x y z. Trapping x ∧ PARP1 y ∧ SitesOfDoubleStrandBreaks z ⟶ (∃e. Increases e ∧ Agent e x ∧ Patient e z ∧ (NonHomologousEndJoining z ∧ Toxicity z))"

(* Explanation 5: PARP inhibitors prevent single strand break repair, which leads to replication-associated double strand breaks. *)
axiomatization where
  explanation_5: "∀x y. PARPInhibitors x ⟶ (∃e. Prevent e ∧ Agent e x ∧ Patient e y ∧ SingleStrandBreakRepair y) ∧ (LeadsTo e ∧ ReplicationAssociatedDoubleStrandBreaks y)"

(* Explanation 6: PARP inhibitors directly cause double strand breaks, which are then repaired through defective homologous recombination repair and error-prone non-homologous end joining. *)
axiomatization where
  explanation_6: "∀x y. PARPInhibitors x ⟶ (∃e. Causes e ∧ Agent e x ∧ Patient e y ∧ DoubleStrandBreaks y) ∧ (RepairedThrough e ∧ (DefectiveHomologousRecombinationRepair y ∧ ErrorProneNonHomologousEndJoining y))"

(* Explanation 7: The prevention of single strand break repair by PARP inhibitors results in replication-associated double strand breaks, which are then repaired through defective homologous recombination repair and error-prone non-homologous end joining. *)
axiomatization where
  explanation_7: "∀x y z. Prevent x ∧ SingleStrandBreakRepair y ∧ PARPInhibitors z ⟶ (LeadsTo e ∧ ReplicationAssociatedDoubleStrandBreaks y) ∧ (RepairedThrough e ∧ (DefectiveHomologousRecombinationRepair y ∧ ErrorProneNonHomologousEndJoining y))"

(* Explanation 8: PARP inhibitors cause double strand breaks by preventing single strand break repair, which leads to replication-associated double strand breaks. *)
axiomatization where
  explanation_8: "∀x y z. PARPInhibitors x ⟶ (∃e. Causes e ∧ Agent e x ∧ Patient e y ∧ DoubleStrandBreaks y) ∧ (Prevent e ∧ SingleStrandBreakRepair y) ∧ (LeadsTo e ∧ ReplicationAssociatedDoubleStrandBreaks y)"

(* Explanation 9: The prevention of single strand break repair by PARP inhibitors leads to a reliance on defective homologous recombination repair and error-prone non-homologous end joining to repair the resulting replication-associated double strand breaks. *)
axiomatization where
  explanation_9: "∀x y z. Prevent x ∧ SingleStrandBreakRepair y ∧ PARPInhibitors z ⟶ (LeadsTo e ∧ ReplicationAssociatedDoubleStrandBreaks y) ∧ (RelianceOn e ∧ (DefectiveHomologousRecombinationRepair y ∧ ErrorProneNonHomologousEndJoining y))"

theorem hypothesis:
  assumes asm: "PARPInhibitors x"
  (* Hypothesis: PARP inhibitors cause replication‐associated double strand breaks by preventing single strand break repair, relying on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA *)
  shows "∃x y e. PARPInhibitors x ∧ Causes e ∧ Agent e x ∧ Patient e y ∧ ReplicationAssociatedDoubleStrandBreaks y ∧ Prevent e ∧ SingleStrandBreakRepair y ∧ RelianceOn e ∧ DefectiveHomologousRecombinationRepair y ∧ ErrorProneNonHomologousEndJoining y"
  by (meson assms explanation_8 explanation_9)
  

end
